Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies

Breast cancer is one of the most common malignancies and the leading cause of cancer-related death in women. HER2 overexpression is a factor for poor prognosis in breast cancer, and anti-HER2 therapy improves survival in these patients. A dual-targeted combination of pertuzumab and trastuzumab, alon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaofan, Yang, Hongjian, Yu, Xingfei, Qin, Jiang-Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540370/
https://www.ncbi.nlm.nih.gov/pubmed/36210846
http://dx.doi.org/10.3389/fphar.2022.1012552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540370/
https://www.ncbi.nlm.nih.gov/pubmed/36210846
http://dx.doi.org/10.3389/fphar.2022.1012552

Ejemplares similares